Yifang Wu
Executive Chairman of the BoardMr. Yifang Wu is Executive Chairman of the Board of Everest Medicines Limited from October 10, 2025. Mr. Wu had been the Chief Executive Officer of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. since June 7, 2016 to June 1, 2022. He served as President of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. since June 7, 2016 until October 29, 2020. He served as Chairman at Shanghai Fosun Pharmaceutical (Group) Co., Ltd since October 29, 2020 until April 29, 2025 and served as Non- Executive Director Since April 29, 2025 until September 30, 2025. Mr. Wu served as the President of Wanbang Biopharmaceuticals Co., Ltd. Mr. Wu has been the Chairman and Chief Executive Officer of Jiangsu Wanbang since April 2011. He serves as Vice President of Fosun Pharmaceutical Industry Co., Ltd. He serves as Vice President of Shanghai Fosun Pharmaceutical Development Co., Ltd. Mr. Wu joined the Fosun Pharma Group in April 2004. Mr. Wu was a Technician, Director, Production Officer, Finance Director, assistant to director of Xuzhou Biochemical Pharmaceutical Factory (now known as Jiangsu Wanbang Biopharmaceutical Company Limited). from June 1987 to April 1997, a Deputy Director of Xuzhou (Wanbang) Biopharmaceuticals Manufactures Plant ( now known as Jiangsu Wanbang) from April 1997 to December 1998, the Deputy General Manager of Xuzhou Wanbang Biochemical Pharmaceutical Co., Ltd. and Deputy General Manager of Jiangsu Wanbang from December 1998 to March 2007 and the President of Jiangsu Wanbang from March 2007 to April 2011. He served as Senior Vice President of Shanghai FOSUN Pharmaceutical (Group) Co., Ltd. from July 17, 2014 to June 7, 2016 and served as its Chief Operating Officer from January 2016 to June 7, 2016. He serves as the Chairman of Jiangsu Wanbang Biochemical Pharmaceuticals Co., Ltd. He was a Non-Executive Director of Shanghai Henlius Biotech, Inc. since 12 June 2015 to August 29, 2025. He had been Non-executive Director of Sisram Medical Ltd until January 1, 2026. He is chairman of the supervisory committee of Sinopharm Group Co., Ltd., all of which are companies listed on the Hong Kong Stock Exchange. He served as a Director of Ambrx, Inc. He has been Executive Director of Shanghai Fosun Pharmaceutical (Group) Co., Ltd since August 31, 2016. He is a CPC member. Mr. Wu graduated from Nanjing University of Science and Technology in 1996; he went on study at China Pharmaceutical University and received his EMBA from Saint Joseph’s University in 2005.
Positions
- Company NameEverest Medicines LimitedStock Code01952PositionExecutive Chairman of the Board
